Stock Events

Stock Events

Mendus AB 

€0.5510
0
+€0.01+1.66% Friday 19:55

Statistics

Day High
0.552
Day Low
0.53
52W High
0.662
52W Low
0.337
Volume
-
Avg. Volume
-
Mkt Cap
35.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2025
Q1 2026
Q2 2026
Next
-0.08
-0.06
-0.05
-0.03
Expected EPS
-0.042368976
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-10.36MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1YG0.STU. It's not an investment recommendation.
Apple
2
AAPL
Tesla
2
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap178.21B
Gilead Sciences, Inc. has a strong portfolio in oncology and cell therapy, competing in the broader cancer treatment market alongside Immunicum.
Novartis
NVS
Mkt Cap260.7B
Novartis AG is a large pharmaceutical company with a significant investment in cancer immunotherapy, making it a competitor in the oncology space.
Merck
MRK
Mkt Cap355.1B
Merck & Co., Inc. is a leader in immunotherapy with its blockbuster drug Keytruda, competing in the oncology market.
AMGEN
AMGN
Mkt Cap204.01B
Amgen Inc. has a diverse portfolio including oncology and inflammatory disease treatments, competing in the biotechnological space for cancer therapies.
Pfizer
PFE
Mkt Cap157.99B
Pfizer Inc. has a broad range of cancer treatments and invests heavily in oncology research, making it a competitor in the cancer therapy market.

About

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Show more...
CEO
Erik Manting
Employees
19
Country
Sweden
ISIN
SE0022239950
WKN
000A40CZ4

Listings

STU
DE
1YG0.STU
F
DE
1YG0.F
MU
DE
1YG0.MU
ST
SE
IMMU.ST

0 Comments

Share your thoughts

FAQ

What is Mendus AB stock price today?▼
The current price of 1YG0.STU is €0.55 EUR — it has increased by +1.66% in the past 24 hours. Watch Mendus AB stock price performance more closely on the chart.
What is Mendus AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Mendus AB stocks are traded under the ticker 1YG0.STU.
Is Mendus AB stock price growing?▼
1YG0.STU stock has fallen by -7.71% compared to the previous week, the month change is a -5.65% fall, over the last year Mendus AB has showed a -11.56% decrease.
What is Mendus AB market cap?▼
Today Mendus AB has the market capitalization of 35.7M
When is the next Mendus AB earnings date?▼
Mendus AB is going to release the next earnings report on November 11, 2026.
What were Mendus AB earnings last quarter?▼
1YG0.STU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.04 EUR resulting in a +24.44% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Mendus AB revenue for the last year?▼
Mendus AB revenue for the last year amounts to 0 EUR.
What is Mendus AB net income for the last year?▼
1YG0.STU net income for the last year is -10.36M EUR.
How many employees does Mendus AB have?▼
As of September 20, 2026, the company has 19 employees.
In which sector is Mendus AB located?▼
Mendus AB operates in the Health & Wellness sector.
When did Mendus AB complete a stock split?▼
Mendus AB has not had any recent stock splits.
Where is Mendus AB headquartered?▼
Mendus AB is headquartered in Stockholm, Sweden.